Company: ZURA
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001104659-25-110793
Chunk: 11

Company: Zura Bio Ltd
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 2
Chunk 11
---
 the modified Rodnan Skin Score (“mRSS”). Key efficacy endpoints include lung disease, assessed by quantitative high-resolution computed tomography (“qHRCT”) and forced vital capacity (“FVC”); physical function, measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI); and the revised Combined Response Index in Systemic Sclerosis (“rCRISS”). Topline results are expected to be available in the fourth quarter of 2026. We continue to monitor timelines and evaluate strategy in light of the competitive landscape for conducting clinical